Newswire (Published: Thursday, May 30, 2019, Received: Thursday, May 30, 2019, 3:55:15 PM CDT)

Word Count: 471

2019 MAY 30 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news reporting originating from Melbourne, Australia, by NewsRx correspondents, research stated, “A key challenge in the management of localized prostate cancer is the identification of men with a high likelihood of progression to an advanced, incurable stage. Patients who harbour germline BRCA2 mutations have worse clinical outcomes than noncarriers when treated with surgery or radiotherapy.”

Financial supporters for this research include National Health and Medical Research Council of Australia, Victorian Government through the Victorian Cancer Agency, Victorian Government through the Victorian Cancer Agency (CAPTIV programme), EJ Whitten Foundation, Peter and Lyndy White Foundation, TissuPath Pathology.

Our news editors obtained a quote from the research from Monash University, “Insights from different disciplines have improved our understanding of why patients with BRCA2-mutant tumours have a high likelihood of failing on conventional management after diagnosis. Treatment-naive BRCA2-mutant tumours are defined by aggressive clinical and molecular features early in the disease course, and the genomic landscape of these BRCA2-mutant tumours is characterized by a unique molecular profile and higher genomic instability than noncarrier tumours. Moreover, BRCA2-mutant tumours commonly show the concurrent presence of the intraductal carcinoma of the prostate (IDCP) pathology, a poor prognostic indicator. Subclonal analyses have revealed that IDCP and invasive adenocarcinoma in BRCA2-mutant tumours can arise from the same ancestral clone, implying that a temporal evolutionary trajectory exists. Finally, functional studies have shown that BRCA2-mutant tumours can harbour a subpopulation of cancer cells that can tolerate castration de novo, enabling the tumour to evade androgen deprivation therapy.”

According to the news editors, the research concluded: “Importantly, future challenges remain regarding how to best model the biology underpinning this aggressive phenotype and translate these findings to improve clinical outcomes.”

For more information on this research see: The Influence of Brca2 Mutation On Localized Prostate Cancer. Nature Reviews Urology, 2019;16(5):281-290. Nature Reviews Urology can be contacted at: Nature Publishing Group, 75 Varick St, 9TH Flr, New York, NY 10013-1917, USA. (Nature Publishing Group -; Nature Reviews Urology -

The news editors report that additional information may be obtained by contacting G.P. Risbridger, Monash University, Monash Partners Comprehens Canc Consortium, Melbourne, Vic, Australia. Additional authors for this research include R.A. Taylor, D.C. Murphy, M. Fraser, P.C. Boutros, R.J. Rebello and R.C. Bristow.

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)


Medical Research Council
Monash University


Australia and New Zealand
North America
United States
New York
New York City


Science and Technology
      Scientific Research
            Medical Research
                  Clinical Outcomes
            Natural Sciences
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
                  Clinical Outcomes
      Medical Specialties and Practices